Market Research Reports, Inc. has announced the addition of “Finland, France, Romania and Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2016” research report to their website www.MarketResearchReports.com

Lewes, DE -- (SBWire) -- 09/13/2016 --Finland will remain amongst the wealthiest countries in the world in real GDP per capita terms, which together with an aging population and a preference for patented medicines, will keep pharmaceutical spending high. However, long-term economic stagnation lies ahead which may push the government to continue to implement additional cost containment measures, therefore creating further revenue earning challenges for drugmakers.

Headline Expenditure Projections
- Pharmaceuticals: EUR2.98bn (USD3.30bn) in 2015 to EUR3.09bn (USD3.31bn) in 2016;+3.8% in local currency terms and +0.1% in US dollar terms. Forecast unchanged from last quarter.

- Healthcare: EUR19.50bn (USD21.63bn) in 2015 to EUR20.12bn (USD21.53bn) in 2016; +3.2% in local currency terms and -0.5% in US dollar terms. Forecast revised upwards slightly from last quarter.

For more information Visit at: http://www.marketresearchreports.com/business-monitor-international/finland-pharmaceuticals-and-healthcare-report-q4-2016

The UK vote to leave the EU will weigh on France's economic growth over the next few quarters, which in turn will pose downside risks to our pharmaceutical and healthcare sector forecasts.

Despite the large pharmaceutical market and high drug spending per capita, which will continue to make France a major global market for drugmakers, market expansion will only resume at a slow pace over the next few years, with return to marginal positive growth in 2017. In line with our view in recent quarters, the rate of investment growth in France's pharmaceutical sector has remained relatively subdued in H116, while this trend will likely continue over the coming quarters, in part due to sluggish labour market reform.

Headline Expenditure Projections
- Pharmaceuticals: EUR33.46bn (USD37.11bn) in 2015 to EUR33.34bn (USD35.68bn) in 2016; -0.3% in local currency terms and -3.9% in US dollar terms. Forecast broadly in line with last quarter.

- Healthcare: EUR251.26bn (USD278.66bn) in 2015 to EUR257.25bn (USD275.26bn) in 2016; +2.4% in local currency terms and -1.2% in US dollar terms. Forecast revised downwards from last quarter.

For more information Visit at: http://www.marketresearchreports.com/business-monitor-international/france-pharmaceuticals-and-healthcare-report-q4-2016

In line with Romania's economic out performance in Europe, the country's pharmaceutical and healthcare markets will see strong growth given increased consumer spending power and higher healthcare contributions. However, aggressive drug pricing regulations, including the imminent joint drug procurement agreement with CEE countries, will limit revenue-earning opportunities.

Headline Expenditure Projections
- Pharmaceuticals: RON14.94bn (USD3.73bn) in 2015 to RON15.89bn (USD3.76bn) in 2016; 6.4% in local currency terms and 0.7% in US dollar terms. Forecast unchanged from last quarter.

- Healthcare: RON39.05bn (USD9.75bn) in 2015 to RON41.28bn (USD9.76bn) in 2016; 5.7% in local currency terms and 0.1% in US dollar terms. Forecast unchanged from last quarter.

For more information Visit at: http://www.marketresearchreports.com/business-monitor-international/romania-pharmaceuticals-and-healthcare-report-q4-2016

The combined value of Saudi Arabia's pharmaceutical and healthcare markets is the largest in the Middle East and Africa region. The Kingdom's National Transformation Program, a key part of Vision 2030, reinstates the government's commitment to improving healthcare provision in the country. Nonetheless, the rising burden of non-communicable diseases will place greater pressure on the country's health services, while opportunities for multinational pharmaceutical companies will develop in line with this. As such, we expect the private sector to play a pivotal role in healthcare expansion in Saudi Arabia over the long term, principally through private health insurance schemes.

Headline Expenditure Projections
- Pharmaceuticals: SAR31.75bn (USD8.46bn) in 2015 to SAR35.14bn (USD9.37bn) in 2016; +10.7% in both local currency and US dollar terms. Forecast in line with Q316.

- Healthcare: SAR142.86bn (USD38.10bn) in 2015 to SAR153.50bn (USD40.91bn) in 2016; +7.4% in local currency terms and US dollar terms. Forecast in line with Q316.

For more information Visit at: http://www.marketresearchreports.com/business-monitor-international/saudi-arabia-pharmaceuticals-and-healthcare-report-q4-2016

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions